Cyclin-dependent Kinases 4/6 Inhibitors in Neuroendocrine Neoplasms: from Bench to Bedside
Purpose of review Cyclin-dependent kinases (CDKs) are key regulators that play an important role in cell division. Palbociclib, ribociclib and abemaciclib showed significant antitumor activity in several malignancies and, recently, also a myeloprotective effect for trilaciclib when added to chemotherapy. The purpose of this review is to highlight the current evidence for CDK4/6 inhibitors in neuroendocrine neoplasms (NENs). Recent findings Preclinical results showed a promising antitumor activity of CDK4/6 inhibitors in neuroendocrine tumors (NETs), but so far, the very few small clinical trials did not show a strong impact on progression free survival (PFS) and objective response in NETs. Meanwhile, the CDK4/6 inhibitor trilaciclib revealed significant effects in reducing chemotherapy-induced myelosuppression in small cell lung cancer (SCLC). Summary Up to date, CDK4/6 inhibitors are still considered investigational in NETs as antitumor agents, whereas trilaciclib can be used in the routine clinical practice in extensive stage SCLC patients for reducing myelotoxicity of standard chemotherapy..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Current oncology reports - 24(2022), 6 vom: 09. März, Seite 715-722 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
de Sousa, Maria João [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Abemaciclib; trilaciclib |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 |
|---|
| doi: |
10.1007/s11912-022-01251-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2078563714 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2078563714 | ||
| 003 | DE-627 | ||
| 005 | 20230513083330.0 | ||
| 007 | tu | ||
| 008 | 221220s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11912-022-01251-x |2 doi | |
| 035 | |a (DE-627)OLC2078563714 | ||
| 035 | |a (DE-He213)s11912-022-01251-x-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a de Sousa, Maria João |e verfasserin |0 (orcid)0000-0003-1125-2871 |4 aut | |
| 245 | 1 | 0 | |a Cyclin-dependent Kinases 4/6 Inhibitors in Neuroendocrine Neoplasms: from Bench to Bedside |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 | ||
| 520 | |a Purpose of review Cyclin-dependent kinases (CDKs) are key regulators that play an important role in cell division. Palbociclib, ribociclib and abemaciclib showed significant antitumor activity in several malignancies and, recently, also a myeloprotective effect for trilaciclib when added to chemotherapy. The purpose of this review is to highlight the current evidence for CDK4/6 inhibitors in neuroendocrine neoplasms (NENs). Recent findings Preclinical results showed a promising antitumor activity of CDK4/6 inhibitors in neuroendocrine tumors (NETs), but so far, the very few small clinical trials did not show a strong impact on progression free survival (PFS) and objective response in NETs. Meanwhile, the CDK4/6 inhibitor trilaciclib revealed significant effects in reducing chemotherapy-induced myelosuppression in small cell lung cancer (SCLC). Summary Up to date, CDK4/6 inhibitors are still considered investigational in NETs as antitumor agents, whereas trilaciclib can be used in the routine clinical practice in extensive stage SCLC patients for reducing myelotoxicity of standard chemotherapy. | ||
| 650 | 4 | |a Neuroendocrine tumors; CDK4/6 inhibitors | |
| 650 | 4 | |a Ribociclib | |
| 650 | 4 | |a Palbociclib | |
| 650 | 4 | |a Abemaciclib; trilaciclib | |
| 700 | 1 | |a Gervaso, Lorenzo |4 aut | |
| 700 | 1 | |a Meneses-Medina, Monica Isabel |4 aut | |
| 700 | 1 | |a Spada, Francesca |4 aut | |
| 700 | 1 | |a Abdel-Rahman, Omar |4 aut | |
| 700 | 1 | |a Fazio, Nicola |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current oncology reports |d Springer US, 1999 |g 24(2022), 6 vom: 09. März, Seite 715-722 |w (DE-627)33429293X |w (DE-600)2057359-5 |w (DE-576)100517684 |x 1523-3790 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2022 |g number:6 |g day:09 |g month:03 |g pages:715-722 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s11912-022-01251-x |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2022 |e 6 |b 09 |c 03 |h 715-722 | ||